
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Healthcare · market cap $34.0B · as of 2026-06-24
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Brexpiprazole, OPC-34712 | Phase 3 | Agitation Associated With |
| OCV-501 | Phase 2 | Acute Myeloid Leukemia |
| JNT-517 Tablet | Phase 3 | Phenylketonuria (PKU) |
| Aripiprazole depot 300 or 400 mg | Phase 3 | Schizophrenia |
| Delamanid + Bedaquiline + OPC-167832 10 mg | Phase 2 | Pulmonary TB |
| Sodium hyaluronate ophthalmic solution | Phase 2 | Keratoconjunctival Epithelial Disorder |
| centanafadine capsule | Phase 3 | Attention Deficit/Hyperactivity Disorder |
| Probucol | Phase 3 | Hyperlipidemia |
| EB-1020 (Centanafadine) 328.8 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| Centanafadine Hydrochloride | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| Tolvaptan Oral Tablet | Phase 3 | Syndrome of Inappropriate Antidiuretic Hormone Secretion |
| 0.3% OPA-15406 | Phase 3 | Atopic Dermatitis |
| 0.3% OPA-15406 Ointment | Phase 3 | Atopic Dermatitis (AD) |
| SEP-363856 75mg | Phase 3 | Schizophrenia |
| Aripiprazole Low (2 mg/day) | Phase 3 | Schizophrenia |
| OPB-31121 | Phase 2 | Hepatocellular Carcinoma |
| Intramuscular (IM) Depot Aripiprazole | Phase 3 | Bipolar I Disorder |
| OPC-64005 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
| OPC-41061 (Tolvaptan) | Phase 3 | Cardiac Edema |
| Sibeprenlimab 400 mg | Phase 3 | Immunoglobulin A Nephropathy |
Daily closes through 2025-12-22. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.